Motley Fool
Suing This Synthetic Biology Pioneer Is Silly
A Fool shakes his Foolish head at a lawsuit brought against Amyris.
3 Pipeline Obesity Treatments You Should Watch
In the past year, two approved obesity drugs put the massive obesity market within reach of investors. Here are three treatments under development that could have even bigger consequences.
JPMorgan's Imperial Chairman Remains
Despite obstacles, JPMorgan shareholders should continue to fight for an independent chair.
This Is 1 Incredible CEO
Under this CEO, this retailer has stepped over its peers, delivering 268% share price gains and dramatically boosting its dividend, while also helping support pediatric cancer research.
Netflix Doesn't Have to Worry About Microsoft's Xbox One
Microsoft's new console won't be the end of Netflix.
Under Armour Kicks It Old School
If you've been missing your old cotton workout clothes, Under Armour has great news.
These Stocks Survived the Dow's Pump-and-Dump Today
Fed Chairman Ben Bernanke head-faked the market out today, but some stocks held onto their gains.
Will Powell Industries Blow It Next Quarter?
Look here for a clue.
Why Vanguard Health Systems's Earnings May Not Be So Hot
All cash flow is not created equal.
Why the Street Should LoveEnergy's Earnings
All cash flow is not created equal.
Why Harris Teeter Supermarkets's Earnings May Not Be So Hot
All cash flow is not created equal.
Why ATMI's Earnings May Not Be So Hot
All cash flow is not created equal.
ValueVision Media Beats on Both Top and Bottom Lines
Just the facts, Fool.
The Unappreciated Awesomeness at Rochester Medical
Don't just count the cash, time it.
The Unappreciated Awesomeness at Globecomm Systems
Don't just count the cash, time it.
Some Numbers at Clearwater Paper that Make Your Stock Look Good
Look here for a clue.
Some Numbers at ABIOMED that Make Your Stock Look Good
Look here for a clue.



